Although the EPR effect and the interaction of albumin with gp60 receptor and SPARC can enhance the accumulation of drug-loaded albumin nanoparticles in tumors, they still have some drawbacks, such as insufficient tumor targeting and weak tumor tissue penetration. The gene discussed is ALB; the disease is neoplasm.